Table 2.

Percentages of patients reaching other secondary efficacy end points

	Acute phase		Delayed phase		Overall phase
	Fosaprepitant (n = 173)	Placebo (n = 167)	Fosaprepitant (n = 173)	Placebo (n = 167)	Fosaprepitant (n = 173)	Placebo (n = 167)
Complete protection	89.6**	77.2	58.4*	45.8a	57.8*	44.3
Total control	67.6	66.5	30.1	22.9a	29.5	22.2
No emesis	93.6***	80.8	68.8***	50.6a	67.6***	49.1
No significant nausea	90.2	84.9a	66.5	58.4a	65.3	58.4a
No nausea	67.6	67.5a	30.6	24.7a	30.1	24.1a
No rescue therapy	100.0**	95.8	78.6	74.3	78.6	74.3

Complete protection: no emesis, no rescue therapy, and no significant nausea (most severe nausea of mild or less severity).

Total control: no emesis, no rescue therapy, and no nausea.

Overall phase: first moderately emetogenic or highly emetogenic antitumour agent (including cisplatin) at 0–120 h after the start of treatment.

Acute phase: first moderately emetogenic or highly emetogenic antitumour agent (including cisplatin) at 0–24 h after the start of treatment.

Delayed phase: first moderately emetogenic or highly emetogenic antitumour agent (including cisplatin) at 24–120 h after the start of treatment.

^an = 166.

*P < 0.05, **P < 0.01, ***P < 0.001 (calculated by the Mantel–Haenszel test after stratification for treatment, sex, presence or absence of at least moderately emetogenic antitumour agent used in combination with cisplatin, and presence or absence of previous treatment with cisplatin).